Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics (NASDAQ: VKTX) reported its Q1 2023 financial results on April 26, 2023, highlighting significant developments in its clinical pipeline. The company completed enrollment in the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis, with data expected in Q2 2023. Viking also announced Phase 1 results for VK2735, showcasing up to 6% placebo-adjusted weight loss and a strong safety profile. The initiation of a Phase 1 trial for an oral formulation of VK2735 was also noted. Financially, Viking completed a public offering raising $287.5 million, enhancing its cash position to approximately $406 million. However, the net loss for the quarter increased to $19.5 million, or $0.25 per share, compared to a loss of $16.1 million, or $0.21 per share in 2022.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will release its financial results for the first quarter of 2023 on
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
